From NCE to NICE: the role of pharmacoeconomics
- PMID: 20716229
- PMCID: PMC2949901
- DOI: 10.1111/j.1365-2125.2010.03708.x
From NCE to NICE: the role of pharmacoeconomics
Comment on
-
Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?Br J Clin Pharmacol. 2010 Sep;70(3):360-6. doi: 10.1111/j.1365-2125.2010.03740.x. Br J Clin Pharmacol. 2010. PMID: 20716236 Free PMC article.
References
-
- Walley T. Drugs, money and society (Part II) Br J Clin Pharmacol. 2010 DOI: 10.1111/j.1365-2125.2009.03569.x. - DOI - PMC - PubMed
-
- Joint Royal Colleges of Physicians Training Board. Specialty training curriculum for Clinical Pharmacology and Therapeutics. August 2010. Available at http://www.jrcptb.org.uk/specialties/ST3-SpR/Documents/2010%20CPT%20Curr... (last accessed 14 June 2010)
-
- Edlin R, Round J, Hulme C, McCabe C. Cost effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists. Br J Clin Pharmacol. 2010 DOI: 10.1111/j.1365-2125.2010.03617.x. - DOI - PMC - PubMed
-
- Hughes DA, Ferner RE. New drugs for old: disinvestment and NICE. BMJ. 2010;340:c572. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
